Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Myotonic dystrophy that is present at birth.
Biomarker and diagnostic research for congenital myotonic dystrophy has been reported in the published literature.
6 clinical trials registered, 6 recruiting. Interventions under study include other interventions, drug therapy, and biologic therapy. Pipeline includes 1 PHASE2, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT02398786](https://clinicaltrials.gov/study/NCT02398786) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:45 AM UTC
Genetic and Rare Diseases Info Center
Myotonic Dystrophy Family Registry
— |
Myotonic Dystrophy Foundation |
RECRUITING |
[NCT00082108](https://clinicaltrials.gov/study/NCT00082108) | Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry | — | University of Rochester | RECRUITING |
[NCT06844214](https://clinicaltrials.gov/study/NCT06844214) | A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 | PHASE1 | Sanofi | RECRUITING |
[NCT06747884](https://clinicaltrials.gov/study/NCT06747884) | Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension | — | Virginia Commonwealth University | RECRUITING |
[NCT05004129](https://clinicaltrials.gov/study/NCT05004129) | Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | PHASE2 | AMO Pharma Limited | RECRUITING |
119 publications have been identified in PubMed for congenital myotonic dystrophy. Research spans Review / Meta-Analysis (37%), Basic Science / Preclinical (28%), and Epidemiology / Natural History (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 44 | 37% |
Laboratory research | 33 | 28% |
Disease patterns and progression | 12 | 10% |
Testing and diagnosis research | 9 | 8% |
Patient case studies | 8 | 7% |
New treatment approaches | 7 | 6% |
Clinical study results | 6 | 5% |
Arechavala-Gomeza V (2026). [PMID: 40150900](https://pubmed.ncbi.nlm.nih.gov/40150900/). *J Neuromuscul Dis*. [Review / Meta-Analysis]
Hensman Moss DJ (2026). [PMID: 41432663](https://pubmed.ncbi.nlm.nih.gov/41432663/). *J Huntingtons Dis*. [Review / Meta-Analysis]
Kiefer M (2026). [PMID: 41938492](https://pubmed.ncbi.nlm.nih.gov/41938492/). *Neurol Genet*. [Epidemiology / Natural History]
Lorca R (2026). [PMID: 41488597](https://pubmed.ncbi.nlm.nih.gov/41488597/). *Int J Cardiol Heart Vasc*. [Epidemiology / Natural History]
Singh S (2026). [PMID: 30085587](https://pubmed.ncbi.nlm.nih.gov/30085587/). *Unknown Journal*. [Epidemiology / Natural History]
De Serres-Bérard T (2026). [PMID: 41644016](https://pubmed.ncbi.nlm.nih.gov/41644016/). *Neurobiol Dis*. [Basic Science / Preclinical]
Russo V (2026). [PMID: 41548716](https://pubmed.ncbi.nlm.nih.gov/41548716/). *J Cardiovasc Magn Reson*. [Review / Meta-Analysis]
Finkel RS (2026). [PMID: 41634391](https://pubmed.ncbi.nlm.nih.gov/41634391/). *Nat Med*. [Clinical Trial Publication]
Suzui R (2026). [PMID: 42037975](https://pubmed.ncbi.nlm.nih.gov/42037975/). *Cureus*. [Case Report / Case Series]
Parwez S (2026). [PMID: 41524923](https://pubmed.ncbi.nlm.nih.gov/41524923/). *Mol Biol Rep*. [Review / Meta-Analysis]